Project 3: In vitro modeling to define mechanisms of childhood vaccine response, susceptibility to respiratory infectious disease and asthma
项目 3:体外建模以确定儿童疫苗反应、呼吸道传染病和哮喘易感性机制
基本信息
- 批准号:10435043
- 负责人:
- 金额:$ 19.86万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-03-10 至 2027-02-28
- 项目状态:未结题
- 来源:
- 关键词:AddressAdjuvantAgeAllergensAnti-Inflammatory AgentsAntigen PresentationAntigensAsthmaAttenuated VaccinesAutologousBCG LiveBiological AssayBiological MarkersBostonCD8-Positive T-LymphocytesCellsChildChild HealthChildhoodClinicalCommunicable DiseasesDataDevelopmentDiseaseEvaluationExposure toFlow CytometryGene Expression ProfilingGoalsGrowthHealthHumanImmuneImmune responseImmunological ModelsImmunomodulatorsIn VitroIndividualInfantInfectionInnate Immune ResponseItalyLeadLeukocytesLifeMHC Class I GenesMediatingMemoryModelingMolecularMononuclearNatural ImmunityParticipantPathway interactionsPattern recognition receptorPediatric HospitalsPeptidesPhenotypePlasmaPopulationPredispositionPrognostic MarkerProteinsPublishingRespiratory DiseaseRespiratory Tract InfectionsRiskRomeSamplingSecondary toShapesSignal PathwaySmall Interfering RNASorting - Cell MovementStimulusSystemSystems BiologyT-Cell ActivationT-LymphocyteTechnologyTestingTrainingTranslatingTranslationsVaccinesadaptive immune responseadaptive immunityage relatedantigen-specific T cellsasthmaticbiobankclinical phenotypecohortcytokinedisorder subtypehuman modelimmune activationin vitro Assayin vitro Modelin vivoinsightmonocyteneutralizing monoclonal antibodiesnovelperipheral bloodprogramsprospectiveprotein expressionprotein metaboliterespiratoryresponsesmall moleculesmall molecule inhibitorvaccine response
项目摘要
Project Summary – Project 3 (PR3)
Immune development in early life (IDEAL) is dynamic and growing evidence suggests that it impacts the
risk for common undesirable clinical phenotypes including low vaccine responsiveness, and proneness to
respiratory infection and/or asthma. However, little is known regarding precise mechanisms nor how to redirect
immune development to more favorable phenotypes. The Precision Vaccines Program (PVP) at Boston Children’s
Hospital (BCH) has developed cutting-edge human in vitro assays which model age related changes in leukocyte
function- i.e., immune ontogeny and population (e.g. age)-specific effects and mechanisms of action of
immunomodulatory agents, including metabolites, proteins, adjuvants and vaccines.
Project 3 (PR3) will leverage human in vitro modeling to gain insight into signaling pathways that are
relevant to the clinical phenotypes observed. Our published and unpublished preliminary data indicate that our
sample-sparing human in vitro assay platforms can model innate and adaptive immune responses of infants and
young children which vary by age and disease status. Our hypothesis is that our innate and adaptive in vitro
modeling platforms can meaningfully interrogate molecular signaling pathways relevant to endotypes
(disease sub-types) of clinical phenotypes such as vaccine responsiveness, respiratory infection and/or
asthma. Our goal is to leverage our cutting-edge human in vitro assay systems to model human immune cell
responses to infant vaccines as well as to confirm, assess and translate the pathways identified in PR1 and PR
2. We will achieve this goal by pursuing the following Specific Aims (SAs): SA1. Assess mechanisms
underlying IDEAL endotypes. In this aim we will pursue molecular interrogation of pathways, biomarkers,
metabolites discovered in PR1 and PR2. SA2. Identify immunomodulators that re-direct trajectories from
unfavorable to favorable endotypes. We will model immune activation in response to agents capable of re-
shaping immune endotypes, including agents that impact the relevant endotype-associated pathways identified
in PR1 and PR2 .
Overall, successful completion of PR3 will provide fresh insight into IDEAL in relation to vaccine
responsiveness, infection and/or asthma proneness. This effort will provide mechanistic insight into IDEAL, help
confirm and probe novel prognostic biomarkers and pathways identified in PR1 and PR2, and identify agents (e.g.,
proteins, metabolites, adjuvants, vaccines) that can redirect human infant leukocytes away from unfavorable
endotypes associated with low vaccine responsiveness, respiratory infection and/or asthma and towards favorable
trajectories and endotypes thereby advancing child health.
项目摘要-项目3(PR 3)
生命早期的免疫发育(IDEAL)是动态的,越来越多的证据表明,它影响着生命早期的免疫发育。
常见不良临床表型的风险,包括低疫苗反应性和
呼吸道感染和/或哮喘。然而,关于精确的机制和如何重定向,
免疫发育到更有利的表型。波士顿儿童医院的精准疫苗计划(PVP)
Hospital(BCH)开发了尖端的人体体外试验,该试验模拟了白细胞中与年龄相关的变化,
功能-即,免疫个体发育和群体(如年龄)特异性效应和作用机制
免疫调节剂,包括代谢物、蛋白质、佐剂和疫苗。
项目3(PR 3)将利用人类体外建模来深入了解
与观察到的临床表型相关。我们已发表和未发表的初步数据表明,
样品保留的人体外测定平台可以模拟婴儿的先天性和适应性免疫应答,
幼儿因年龄和疾病状况而异。我们的假设是,我们的先天和适应性在体外
建模平台可以有意义地询问与内型相关的分子信号传导途径,
(疾病亚型)的临床表型,如疫苗反应性、呼吸道感染和/或
哮喘我们的目标是利用我们最先进的人体体外分析系统来模拟人体免疫细胞
对婴儿疫苗的反应以及确认、评估和翻译PR 1和PR中确定的途径
2.我们将通过追求以下具体目标来实现这一目标:评估机制
基础IDEAL内型。在这一目标中,我们将追求的分子审讯的途径,生物标志物,
在PR 1和PR 2中发现的代谢物。SA 2.识别免疫调节剂,
不利于有利的内型。我们将模拟免疫激活,以响应能够重新激活的试剂。
塑造免疫内型,包括影响已鉴定的相关内型相关途径的药物
在PR 1和PR 2。
总体而言,PR 3的成功完成将为IDEAL与疫苗的关系提供新的见解
反应性、感染和/或哮喘倾向。这项工作将提供对理想的机械洞察力,帮助
确认和探测在PR 1和PR 2中鉴定的新的预后生物标志物和途径,并鉴定试剂(例如,
蛋白质、代谢物、佐剂、疫苗),可以将人类婴儿白细胞从不利的
与低疫苗应答性、呼吸道感染和/或哮喘相关的内型,
从而促进儿童健康。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
OFER LEVY其他文献
OFER LEVY的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('OFER LEVY', 18)}}的其他基金
Immune development in early life (IDEAL) shapes vaccine response, respiratory infectious diseaseand asthma
生命早期的免疫发育 (IDEAL) 影响疫苗反应、呼吸道传染病和哮喘
- 批准号:
10435035 - 财政年份:2022
- 资助金额:
$ 19.86万 - 项目类别:
Project 3: In vitro modeling to define mechanisms of childhood vaccine response, susceptibility to respiratory infectious disease and asthma
项目 3:体外建模以确定儿童疫苗反应、呼吸道传染病和哮喘易感性机制
- 批准号:
10589826 - 财政年份:2022
- 资助金额:
$ 19.86万 - 项目类别:
Immune development in early life (IDEAL) shapes vaccine response, respiratory infectious diseaseand asthma
生命早期的免疫发育 (IDEAL) 影响疫苗反应、呼吸道传染病和哮喘
- 批准号:
10589800 - 财政年份:2022
- 资助金额:
$ 19.86万 - 项目类别:
Administrative Core: IDEAL shapes vaccine response, susceptibility to respiratory infectious disease and asthma
管理核心:IDEAL 影响疫苗反应、呼吸道传染病和哮喘的易感性
- 批准号:
10435036 - 财政年份:2022
- 资助金额:
$ 19.86万 - 项目类别:
Administrative Core: IDEAL shapes vaccine response, susceptibility to respiratory infectious disease and asthma
管理核心:IDEAL 影响疫苗反应、呼吸道传染病和哮喘的易感性
- 批准号:
10589801 - 财政年份:2022
- 资助金额:
$ 19.86万 - 项目类别:
IMPACC convalescent data collection, including Patient Reported Outcomes (PROs) and home visit sampling
IMPACC 恢复期数据收集,包括患者报告结果 (PRO) 和家访抽样
- 批准号:
10290547 - 财政年份:2021
- 资助金额:
$ 19.86万 - 项目类别:
IMPACC convalescent data collection, including Patient Reported Outcomes (PROs) and home visit sampling
IMPACC 恢复期数据收集,包括患者报告结果 (PRO) 和家访抽样
- 批准号:
10205742 - 财政年份:2021
- 资助金额:
$ 19.86万 - 项目类别:
Newborn cohorts to discover and validate biomarkers of neonatal vaccine immunogenicity
新生儿队列发现和验证新生儿疫苗免疫原性的生物标志物
- 批准号:
10323182 - 财政年份:2020
- 资助金额:
$ 19.86万 - 项目类别:
Systems Biology to Identify Biomarkers of Neonatal Vaccine Immunogenicity
识别新生儿疫苗免疫原性生物标志物的系统生物学
- 批准号:
10221106 - 财政年份:2020
- 资助金额:
$ 19.86万 - 项目类别:
Systems Biology to Identify Biomarkers of Neonatal Vaccine Immunogenicity
识别新生儿疫苗免疫原性生物标志物的系统生物学
- 批准号:
10265669 - 财政年份:2020
- 资助金额:
$ 19.86万 - 项目类别:
相似海外基金
Restoring age-dependent vaccine unresponsiveness by a novel ASP-1 adjuvant combination
通过新型 ASP-1 佐剂组合恢复年龄依赖性疫苗无反应
- 批准号:
10458553 - 财政年份:2021
- 资助金额:
$ 19.86万 - 项目类别:
Restoring age-dependent vaccine unresponsiveness by a novel ASP-1 adjuvant combination
通过新型 ASP-1 佐剂组合恢复年龄依赖性疫苗无反应
- 批准号:
10220588 - 财政年份:2021
- 资助金额:
$ 19.86万 - 项目类别:
Restoring age-dependent vaccine unresponsiveness by a novel ASP-1 adjuvant combination
通过新型 ASP-1 佐剂组合恢复年龄依赖性疫苗无反应
- 批准号:
10620718 - 财政年份:2021
- 资助金额:
$ 19.86万 - 项目类别:
CoVPN 3005 - Efficacy, Immunogenicity, and Safety of SARS-CoV-2 Recombinant Protein Vaccine with Adjuvant in Adults 18 Years of Age and Older
CoVPN 3005 - SARS-CoV-2 重组蛋白疫苗与佐剂对 18 岁及以上成人的功效、免疫原性和安全性
- 批准号:
10415762 - 财政年份:2021
- 资助金额:
$ 19.86万 - 项目类别:
Dissecting the mechanism of age-specific adjuvant synergy in vitro and in vivo
剖析年龄特异性佐剂体外和体内协同作用的机制
- 批准号:
9108575 - 财政年份:2016
- 资助金额:
$ 19.86万 - 项目类别:
CoVPN 3005: Efficacy, Immunogenicity, and Safety of Two SARS-CoV-2 Recombinant Protein Vaccines with Adjuvant in Adults 18 Years of Age and Older - LC 3
CoVPN 3005:两种 SARS-CoV-2 重组蛋白疫苗与佐剂对 18 岁及以上成人的功效、免疫原性和安全性 - LC 3
- 批准号:
10570739 - 财政年份:2006
- 资助金额:
$ 19.86万 - 项目类别:
CoVPN 3005 - Efficacy, Immunogenicity, and Safety of SARS-CoV-2 Recombinant Protein Vaccine with Adjuvant in Adults 18 Years of Age and Older
CoVPN 3005 - SARS-CoV-2 重组蛋白疫苗与佐剂对 18 岁及以上成人的功效、免疫原性和安全性
- 批准号:
10686595 - 财政年份:2006
- 资助金额:
$ 19.86万 - 项目类别:
CoVPN 3005 - Efficacy, Immunogenicity, and Safety of Two SARS-CoV-2 Recombinant Protein Vaccines with Adjuvant in Adults 18 Years of Age and Older
CoVPN 3005 - 两种 SARS-CoV-2 重组蛋白疫苗与佐剂对 18 岁及以上成年人的功效、免疫原性和安全性
- 批准号:
10581414 - 财政年份:2006
- 资助金额:
$ 19.86万 - 项目类别:
CoVPN 3005 - Efficacy, Immunogenicity, and Safety of SARS-CoV-2 Recombinant Protein Vaccine with Adjuvant in Adults 18 Years of Age and Older
CoVPN 3005 - SARS-CoV-2 重组蛋白疫苗与佐剂对 18 岁及以上成人的功效、免疫原性和安全性
- 批准号:
10579557 - 财政年份:2006
- 资助金额:
$ 19.86万 - 项目类别: